Cisplatin and Vinorelbine Treatment Regimen for Lung Cancer
In this article
The Cisplatin and Vinorelbine combinationis a standard platinum doublet with a proven postoperative (adjuvant) survival benefit in non-small cell lung cancer (NSCLC) and high efficacy in locally advanced/metastatic disease. The regimen requires intensive supportive care because of its high emetogenic potential and nephrotoxicity risk.
- Cisplatin (Alkylating-Like Agent): After entering the cell, it forms crosslinks between DNA strands. This damage prevents DNA replication and transcription, driving the cancer cell into apoptosis (programmed cell death).
- Vinorelbine (Vinca Alkaloid): It disrupts microtubule dynamics. By inhibiting polymerization of tubulin, the building block of the cellular cytoskeleton, it arrests the cell during division (M phase) and kills it.
Note: The two drugs’ different mechanisms (DNA damage + mitotic arrest) create a synergistic effect.
- Adjuvant (After Surgery): To reduce recurrence risk and prolong overall survival by eliminating microscopic disease in stage IB, II and IIIA patients (standard of care).
- Neoadjuvant (Before Surgery): To increase the chance of operability by reducing tumor size.
- Locally Advanced/Metastatic: With curative intent concurrently with radiotherapy (chemoradiotherapy), or to prolong life in metastatic disease.
- Adjuvant NSCLC: One of the cisplatin-based regimens with the strongest evidence (IALT, ANITA trials). Usually 4 cycles are recommended.
- Guidelines: NCCN (v.2024) and ESMO recommend it as a preferred platinum doublet for patients with good performance status (PS 0-1).
- Türkiye (SGK): Reimbursed under SUT for a diagnosis of lung cancer.
- Hydration (MANDATORY): At least 2-3 liters of normal saline + Mg/K supplementation before and after Cisplatin.
- Cisplatin: 75 – 80 mg/m² IV infusion over 2 hours (Day 1 only).
- Vinorelbine: 25 – 30 mg/m² IV infusion or bolus over 10-15 min (Day 1 and Day 8).
- Cycle: Repeated every 21 days. A total of 4 cycles are planned for adjuvant treatment.
- Renal Function (eGFR): Cisplatin is nephrotoxic. If creatinine clearance is < 60 mL/min, Cisplatin is generally withheld or the dose reduced (consider switching to Carboplatin).
- Complete Blood Count (Neutrophils): Particularly before the Day 8 Vinorelbine dose, the absolute neutrophil count (ANC) must be checked. If ANC is < 1500/mm³, omit the day 8 dose.
- Hearing Test: Baseline audiometry is recommended (particularly if tinnitus is reported).
- Electrolytes: Low magnesium and potassium are common, and replacement may be needed before treatment.
- Leakage Outside the Vein (Extravasation): Vinorelbine is a potent vesicant (causes tissue injury). If pain/burning occurs during infusion, stop immediately and apply cold or heat (hyaluronidase according to institutional protocol). A port catheter is preferred if possible.
- Urine Output: On the day of Cisplatin, ensure ample urine output (for example, >100 cc per hour). Use Mannitol if needed.
- Constipation Management: Vinorelbine can slow bowel movements through its neurotoxic effects. Fiber-rich foods and laxative support are recommended.
- Renal Failure: If creatinine rises despite hydration, discontinue Cisplatin and switch to Carboplatin.
- Neuropathy: Cisplatin and Vinorelbine can cause cumulative neuropathy. If numbness in the hands and feet affects daily life (Grade 2+), dose reduction or a change of drug is required.
- Hearing Loss: Difficulty hearing high-frequency sounds or tinnitus may be permanent.
- Older Patients: Comorbidities and performance status may reduce Cisplatin tolerability. “Split dosing” (dividing the dose across days) or Carboplatin as an alternative may be considered.
| Situation | Recommendation | Note |
|---|---|---|
| Day 8 Neutropenia (ANC < 1500) | That day’s Vinorelbine dose should be OMITTED (skipped) | The dose is canceled outright rather than delayed. |
| History of Febrile Neutropenia | G-CSF support in subsequent cycles or a 20% dose reduction | Infection risk is high. |
| Nephrotoxicity (Creatinine > 1.5) | Hold Cisplatin or switch to Carboplatin | Increase hydration. |
| Severe Neuropathy / Ototoxicity | Stop the relevant drug (Cisplatin/Vinorelbine) | Risk of permanent damage. |
Dose adjustments should always follow the physician’s clinical judgment and patient-specific factors.
Cisplatin (Platinum)
| Frequency | Side Effect | Management Tip |
|---|---|---|
| >20% | Nausea and Vomiting (Acute/Delayed) | An NK1 + 5HT3 + Steroid combination is essential. Olanzapine may be added. |
| >20% | Nephrotoxicity (Kidney damage) | Aggressive hydration (Pre/Post). Avoid NSAIDs (painkillers). |
| 10–20% | Ototoxicity (Tinnitus/Hearing loss) | Ask about symptoms; audiometry if needed. May be permanent. |
| 1–10% | Electrolyte Disturbance (Low Mg/K) | Routine blood monitoring and intravenous replacement. |
Vinorelbine (Vinca Alkaloid)
| Frequency | Side Effect | Management Tip |
|---|---|---|
| >20% | Neutropenia (Low white blood cell count) | Blood counts are critical, particularly before the day 8 dose. Seek urgent care for fever. |
| 10–20% | Constipation | Fiber-rich diet, plenty of water and laxatives. Risk of bowel paralysis (ileus). |
| 10–20% | Infusion Site Reaction (Phlebitis) | Redness/pain along the vein after infusion. A port is recommended. |
| 1–10% | Peripheral Neuropathy | Numbness in the fingertips. Vitamin B supplementation is controversial. |
Frequencies are generalized from clinical trials (IALT, ANITA); individual responses may vary.
The Cisplatin + Vinorelbine regimen is an established lung cancer treatment with a clear survival benefit, but its toxicity management requires discipline. For successful treatment, adequate hydration, strong antiemetics and monitoring of the day 8 dose play a key role.
1) Arriagada R, et al. (IALT Study). Cisplatin-based adjuvant chemotherapy in patients with completely resected NSCLC. N Engl J Med 2004.
2) Douillard JY, et al. (ANITA Trial). Adjuvant vinorelbine plus cisplatin versus observation... Lancet Oncol 2006.
3) NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, v.2024.
4) ESMO Guidelines: Early and Locally Advanced NSCLC (2023 update).
5) T.C. Sağlık Bakanlığı – SUT Geri Ödeme Kuralları (2025).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.